EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn’s Disease

Suzanne I Anjie iD, Geert R D'Haens, Filip Baert, Peter Bossuyt iD, Frank Hoentjen, Esmé Clasquin, Tamás Molnár, Mark Löwenberg, Séverine Vermeire iD, J Carl Panetta, Thierry Dervieux

Inflammatory Bowel Diseases · 01.02.2026 · 32 (2) · 390-393

DOI: 10.1093/ibd/izaf255 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 10.11.2025. Verfasst von Suzanne I Anjie und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, Netherlands. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Prometheus Laboratories to AmsterdamUMC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lay Summary Vedolizumab clearance (CL) outperforms serum trough concentrations in predicting therapeutic outcomes in Crohn’s disease. Higher CL was significantly associated with reduced remission rates, supporting CL as a pharmacokinetic marker for optimizing vedolizumab therapy.

Schlagwörter

Stichwörter der Autor:innen

ClearanceCrohn's diseaseVedolizumab

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, Netherlands.
  • Az Delta, Department of Gastroenterology, Roeselare, Belgium.
  • Imelda General Hospital, Bonheiden, Belgium.
  • Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, Netherlands.
  • Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada.
  • Department of Internal Medicine, University of Szeged, Szeged, Hungary.

ORCID-Profile: Suzanne I Anjie, Peter Bossuyt, Séverine Vermeire

Förderung

  • Prometheus Laboratories to AmsterdamUMC

Zitieren

APA

Anjie, S. I., D'Haens, G. R., Baert, F., Bossuyt, P., Hoentjen, F., Clasquin, E., Molnár, T., Löwenberg, M., Vermeire, S., Panetta, J. C., & Dervieux, T. (2026). Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn’s Disease. Inflammatory Bowel Diseases, 32(2), 390-393. https://doi.org/10.1093/ibd/izaf255

Vancouver

Anjie SI, D'Haens GR, Baert F, Bossuyt P, Hoentjen F, Clasquin E, et al. Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn’s Disease. Inflammatory Bowel Diseases. 2026;32(2):390-393. doi:10.1093/ibd/izaf255

BibTeX
@article{Anjie2026,
  author = {Anjie, Suzanne I and D'Haens, Geert R and Baert, Filip and Bossuyt, Peter and Hoentjen, Frank and Clasquin, Esmé and Molnár, Tamás and Löwenberg, Mark and Vermeire, Séverine and Panetta, J Carl and Dervieux, Thierry},
  title = {Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn’s Disease},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  volume = {32},
  number = {2},
  pages = {390--393},
  doi = {10.1093/ibd/izaf255}
}
Kostenlos starten →